bluebird bio Decision to Separate its Businesses
bluebird bio (BLUE) will retain focus on its severe genetic disease (SGD) and will launch its oncology business (Oncology Newco) as a new entity. The Board of Directors at bluebird bio approved this decision and it is anticipated that the spin-out of Oncology Newco is to be tax-free . . .
This content is for paid subscribers.
Impacting News January 14, 2021